BACKGROUND: The management of patients with liver metastases presents a challenging problem in clinical oncology. Patients with limited involvement of the liver may be suitable for surgical resection or local ablative techniques. Stereotactic body radiotherapy (SBRT) presents an emerging new technology that has shown high efficacy in ablating tumors at various disease sites. METHODS: A comprehensive literature search was performed to identify articles in regard to the SBRT in the treatment of patients with liver metastases. RESULTS: SBRT allows for the delivery of high-dose radiation in few fractions to the tumor with extreme accuracy, while minimizing the damage to normal surrounding tissue. The CyberKnife® system is an image-guided robotic system that delivers SBRT, tracks tumors during respiration, and automatically adjusts treatment for any patient movement. The most frequently used indications for CyberKnife® therapy are ≤5 liver metastases with maximum tumor sizes of 6 cm, no extrahepatic disease, good performance status, and adequate hepatic functions. Local control rates range from 70%-100% at 1 year and from 60%-90% at 2 years. Severe toxicity related to SBRT is uncommon - grade three side effects occur in less than 5% of cases. Despite excellent local control rates, out-of-field metastatic progression (out-of-field hepatic metastases and extrahepatic metastases) develops in a substantial proportion of patients after SBRT. Therefore, it seems essential to improve the selection of patients with liver metastases for SBRT. CONCLUSION: The CyberKnife® system presents an effective minimally invasive treatment modality for patients with hepatic oligometastases who are not suitable candidates for radical liver resection. The available data suggest that liver metastases can be treated by CyberKnife therapy with very low toxicity and excellent local control rates.

Department of Oncology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Surgery University Hospital Ostrava Ostrava Czech Republic

Department of Surgical Studies Faculty of Medicine University of Ostrava Ostrava Czech Republic

Zobrazit více v PubMed

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature deaths. CA Cancer J Clin. 2011;61(4):212–236. PubMed

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–766. PubMed PMC

Khan K, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first of palliation alone? World J Gastroenterol. 2014;20(35):12391–12406. PubMed PMC

Grundmann RT. Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg. 2011;3(12):183–196. PubMed PMC

Ihnát P, Ihnát Rudinská L, Zonča P. Radiofrequency energy in surgery: state of the art. Surg Today. 2014;44(6):985–991. PubMed

Dieterich S, Gibbs IC. The CyberKnife in clinical use: current roles, future expectations. Front Radiat Ther Oncol. 2011;43:181–194. PubMed

Ihnát P, Vávra P, Zonča P. Treatment strategies for colorectal carcinoma with synchronous liver metastases: which way to go? World J Gastroenterol. 2015;21(22):7014–7021. PubMed PMC

Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–e37. PubMed

Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012;82(3):1047–1057. PubMed

Berkovic P, Gulyban A, Nguyen PV, et al. Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligorecurrence. Clin Colorectal Cancer. 2017;16(4):349–357. PubMed

Yuan ZY, Meng MB, Liu CL, et al. Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases. Onco Targets Ther. 2014;7:915–923. PubMed PMC

Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951;102(4):316–319. PubMed

Wowra B, Muacevic A, Tonn JC. CyberKnife radiosurgery for brain metastases. Prog Neurol Surg. 2012;25:201–209. PubMed

Kato H, Yoshida H, Taniguch H, et al. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol. 2015;21(46):13101–13112. PubMed PMC

Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76(2):326–332. PubMed

Adler JR, Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. The Cyberknife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg. 1997;69(1–4 Pt 2):124–128. PubMed

Peiffert D, Baumann AS, Marchesi V. Treatment of hepatic metastases of colorectal cancer by robotic stereotactic radiation (Cyberknife®) J Visc Surg. 2014;151(Suppl 1):S45–S49. PubMed

Lemke J, Cammerer G, Ganser J, et al. Survival and prognostic factors of colorectal liver metastases after surgical and nonsurgical treatment. Clin Colorectal Cancer. 2016;15(4):e183–e192. PubMed

Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301. PubMed PMC

Pereira PL. Actual role of radiofrequency ablation of liver metastases. Eur Radiol. 2007;17(8):2062–2070. PubMed

Nikfarjam M, Muralidharan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J Surg Res. 2005;127(2):208–223. PubMed

Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10(9):1059–1069. PubMed PMC

Kress MS, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K. Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes. Front Oncol. 2012;2:8. PubMed PMC

Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–4069. PubMed

Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–1087. PubMed

Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys. 2011;81(3):e39–e47. PubMed

van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377–382. PubMed

Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol. 2006;45(7):831–837. PubMed

Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–1591. PubMed

Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–1578. PubMed

Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol. 2012;7:166. PubMed PMC

Fumagalli I, Bibault JE, Dewas S, et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol. 2012;7:164. PubMed PMC

McPartlin A, Swaminath A, Wang R, et al. Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys. 2017;99(2):388–395. PubMed

Aitken K, Tree A, Thomas K, et al. Initial UK experience of stereotactic body radiotherapy for extracranial oligometastases: can we change the therapeutic paradigm? Clin Oncol. 2015;27(7):411–419. PubMed

Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cárdenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6(2):86–95. PubMed

Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(5):1516–1522. PubMed

Stintzing S, Grothe A, Hendrich S, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–977. PubMed

Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–830. PubMed

Palacios-Eito A, Garcia-Cabezas S. Oligometastatic disease, the curative challenge in radiation oncology. World J Clin Oncol. 2015;6(4):30–34. PubMed PMC

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. PubMed

Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107–111. PubMed PMC